Presidential Symposium
(Webcasts Abstracts S149, S151, S152, S154 see Press Briefing 1)
(S149) FIRST-IN-HUMAN CLL1-CD33 COMPOUND CAR T CELLS AS A TWO-PRONGED APPROACH FOR THE TREATMENT OF REFRACTORY ACUTE MYELOID LEUKEMIA Abstract S149
Fang Liu (Department of Hematology,Chengdu Military General Hospital,Chengdu,China)
(S150) RIBOSOMAL LESIONS PROMOTE ONCOGENIC MUTAGENESIS Abstract S150
Sergey Sulima (Oncology,KU Leuven,Leuven,Belgium)
(S151) OVERALL SURVIVAL BENEFIT OF OBINUTUZUMAB OVER RITUXIMAB WHEN COMBINED WITH CHLORAMBUCIL IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND COMORBIDITIES: FINAL SURVIVAL ANALYSIS OF THE CLL11 STUDY Abstract S151)
Valentin Goede (German CLL Study Group, Department I of Internal Medicine, Center of Integrated Oncology,University Hospital,Cologne,Germany;Oncogeriatric Unit, Department of Geriatric Medicine,St Marien Hospital,Cologne,Germany)
(S152) CHRONIC RED BLOOD CELL TRANSFUSIONS IMPAIR THE INNATE IMMUNE RESPONSE TO INFECTIOUS CUES BY SHAPING MACROPHAGES TOWARDS AN ANTI-INFLAMMATORY FUNCTIONAL PHENOTYPE. Abstract S152
Francesca Vinchi (Iron Research Program,New York Blood Center,New York,United States)
(S153) MPN CALR MUTANTS PROMOTE CELL-SURFACE LOCALIZATION OF TPOR WHICH IS OBLIGATORY FOR ONCOGENESIS: NOVEL THERAPEUTIC AVENUES AND RESCUE OF CONGENITAL THROMBOCYTOPENIA TPOR MUTANTS Abstract S153
Christian Pecquet (Signal Transduction Unit,Ludwig Institut for Cancer Research Ltd,Brussels,Belgium)
(S154) RELEVANCE: PHASE III EFFICACY AND SAFETY STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VERSUS RITUXIMAB PLUS CHEMOTHERAPY, FOLLOWED BY RITUXIMAB, IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA Abstract S154
Frank Morschhauser (Department d' Hematologie,Centre Hospitalier Universitaire Régional de Lille, Unité GRITA,Lille,France)